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incidence/epidemiology
Lung cancer is the leading cause of cancer mortality worldwide,
accounting for ∼1.3 million deaths each year. Overall incidence
and epidemiology data are summarised in the ESMO Clinical
Practice Guidelines (CPG) on ‘metastatic non-small-cell lung
cancer (NSCLC)’ [1].
screening for lung cancer
A high proportion of NSCLC patients present with symptoms
in advanced disease stage. The aim of lung cancer screening is to
reduce lung cancer-related mortality by detecting more patients
in earlier—potentially curable—stages. Historical randomised,
controlled trials (RCTs) on the use of periodical chest X-ray
and/or sputum cytology were negative, and screening based on
these techniques is therefore not recommended [I, C]. Low-dose
computed tomography (LDCT)—more sensitive for the
detection of small nodules—was studied in more recent RCTs.
The National Lung Screening Trial (NLST) compared LDCT
with chest X-ray in 53 454 current or former heavy smokers
(≥30 pack-years or ≤15 years since smoking cessation) aged
between 55 and 74 years. In this high-risk group, a 20%
reduction in lung cancer related deaths, from 425 to 326
(P = 0.004), was reported. All-cause mortality was reduced by
6.7% [2]. LDCT screening thus reduces lung cancer-related
mortality [I, A]. It is, however, not ready for large-scale
population-based implementation because of remaining questions
surrounding the deﬁnition of the at-risk population, timing,
interval and method of computed tomography (CT) (particularly
2D versus 3D nodule interpretation [3]), how to handle (false)
positive ﬁndings and, especially, cost-effectiveness when compared
with, e.g. smoking cessation alone [4]. Further analyses and results
of several ongoing European trials are eagerly awaited.
Other potential methods of screening, such as exhaled breath
or blood biomarkers lack validation and are therefore not
recommended in clinical practice [II, C].
diagnosis
Bronchoscopy is the appropriate test for centrally located
tumours, where a pathological diagnosis will be obtained in
∼90% of cases by means of forceps biopsy, bronchial brushing
or washing [III, A]. For the pathological classiﬁcation, we refer
to the diagnostic paragraph in the CPG ‘metastatic non-small-
cell lung cancer (NSCLC)’ [1].
the solitary pulmonary nodule
Peripheral lesions, especially solitary pulmonary nodules, are a
diagnostic challenge. Typical calciﬁcation patterns usually point
to a benign aetiology. Likewise, a solid nodule that has been
stable for at least 2 years upon comparison with prior imaging
results is very likely to be benign. Factors such as age, smoking
history, size, borders or density can be of help in risk
assessment, but do not replace evaluation by an experienced
multidisciplinary team. Teams are strongly encouraged to follow
existing guidelines of pulmonary or imaging societies for initial
solitary pulmonary nodule management [III, A]. Examples are
the recently revised American College of Chest Physicians
(ACCP) guidelines [5], or the Fleishner Society
recommendations for small solid nodules [6] or for sub-solid
nodules [7].
In nodules considered suspect, a pre-treatment pathological
proof, preferably obtained by biopsy, is recommended [III, A].
Appropriate techniques are peripheral sampling by
bronchoscopy [directed by either radial endobronchial
ultrasound (EBUS) or navigational CT], tru-cut biopsy under
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CT guidance or video-assisted thoracoscopy (VATS) biopsy.
However, in some patients with clinical stage I/II lesions,
diagnostic samples may not be accessible and resection or
stereotactic ablative radiotherapy (SABR) may be selected if
there is a high likelihood of malignancy based on assessment of
clinical and imaging ﬁndings by an experienced
multidisciplinary group [III, A].
staging and risk assessment
The overall staging and risk assessment is summarised in the
CPG ‘metastatic non-small cell lung cancer (NSCLC)’ [1].
locoregional staging
After distant metastases have been ruled out, a more detailed
locoregional staging is mandatory to distinguish early stages
(I/II) from potentially resectable stage IIIA and from
unresectable stage III, according to the seventh TNM staging
system [8] [III, A]. This is a multidisciplinary process involving
imaging, endoscopic and surgical techniques [9]. Accuracy is
vital to avoid erroneous interpretations leading to a false stage
III or stage IV diagnosis in early-stage patients and vice versa.
Absence of suspect mediastinal lymph node (LN) metastasis
on both CT and positron emission tomography (PET) images
has a high negative predictive value, and these patients can in
general proceed to surgery, except in the case of a centrally
located tumour or hilar LNs
[I, A]. In these cases the probability of mediastinal LN disease is
increased and may also be obscured on imaging [10].
In patients with mediastinal LNs on imaging, The ACCP
makes the distinction between discrete (non-bulky) LNs (i.e.
discrete nodes seen on CT, well enough deﬁned to measure their
size) and extensive (bulky) LN inﬁltration (i.e. nodes can no
longer be distinguished or measured, multiple nodes are matted
together and the boundary between them is obscured,
mediastinal vessels may be encircled) [10]. Except for those with
bulky LN disease, nodal tissue conﬁrmation is recommended
[11] [I, A]. For that purpose, endoscopic techniques such as
endobronchial (EBUS) or oesophageal ultrasound (EUS)-guided
sampling by expert teams are preferred as a ﬁrst step to conﬁrm
LN disease, as they are less invasive and less costly than
mediastinoscopy [I, A]. For patients with suspect LNs on
imaging and negative EBUS/EUS results, an additional
mediastinoscopy is recommended [12]. Figure 1 provides a
practical schematic for rational locoregional staging.
preoperative risk assessment
In patients scheduled for radical treatment (surgery alone,
surgical or non-surgical combined modality treatment), risk
assessment is an integral aspect to allow joint decision-making
with the patient, even if data supporting its relevance in
decision-making are limited [III, A].
If pulmonary function tests point to a forced expiratory
volume in 1 s (FEV1) and diffusing capacity for carbon
monoxide (DLCO) >80%, patients can proceed to surgery
without further pulmonary evaluation [13] [III, A]. When either
FEV1 or DLCO is <80%, additional ergospirometry helps to
assess the risk for postoperative complications or mortality.
Patients with a maximal oxygen consumption (VO2max) >20
ml/kg/min may proceed to surgery as far as pneumonectomy,
while those with a VO2max <10 ml/kg/min have a very high
postoperative risk [13] [III, A]. For the others, more formal lung
function testing—including segment counting used to estimate
postoperative lung function—is needed, as the risk of
postoperative shortness of breath is important to both the
patient and clinician. As a guide, a predicted postoperative
FEV1 and DLCO >40% is acceptable [14].
The risk of in-hospital death can also be also estimated using
a validated scoring method such as the Thoracoscore [15] [III,
A]. There have been a number of risk models to predict adverse
cardiac outcomes, but they do not seem to discriminate well in
patients undergoing thoracic surgery [16].
It is best practice to evaluate and optimise any co-morbidities
[chronic obstructive pulmonary disease (COPD), heart failure,
ischaemic heart disease, diabetes, renal insufﬁciency,
coagulation disorders] before planned surgery [14] [III, A].
treatment of early stages I and II
surgery
Surgery remains the cornerstone of treatment of early-stage
NSCLC for patients willing to accept the procedure-related risks
[III, A]. Those not willing to accept these risks should be
informed about other radical options such as SABR. Current
randomised trials comparing surgery with stereotactic body
radiotherapy in patients with stage I disease will be relevant for
future guideline and policy recommendations.
Based on data from the LSCG 821 trial, lobectomy is the
current treatment of choice (given sufﬁcient lung function)
[I, A]. More limited resections (segmentectomy and wedge
resection) are associated with increased local recurrence [17].
The optimum extent of resection for small lesions (<2 cm),
adenocarcinoma in situ and minimally invasive
adenocarcinoma are the subject of investigations in randomised
trials and cohort studies, respectively.
In terms of LN management, randomised trials have not
solved the controversial issue of LN sampling versus systematic
nodal dissection. These two options do not differ in terms of
complication rates, but data are conﬂicting with respect to
survival outcome [18, 19]. The extent of LN dissection is
therefore nowadays mainly dictated by staging requirements for
guaranteed ‘R0 resection’ status. This is stipulated by the
International Association for the Study of Lung Cancer (IASLC)
as a minimum of six nodes/stations, three of which should be
mediastinal including the sub-carinal station, with negativity of
the highest resected node [20] [III, A].
Minimal access surgery (VATS lobectomy) is increasingly
carried out. A systematic review reported improved 5-year
survival and reduced systemic recurrences in patients who
received VATS lobectomy [21], and another meta-analysis
reported lower in-hospital complications [22]. It is important to
appreciate, however, that most of the comparative studies
included were non-randomised; and hence, there is a possibility
of selection bias inﬂuencing good outcomes for VATS
lobectomy. To date there have not been any RCTs sufﬁciently
powered to detect important differences between the two
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techniques in either overall or disease-free survival. Either open
thoracotomy or VATS access can thus be utilised as appropriate
to the expertise of the surgeon [III, A].
chemotherapy
There is a broad evidence base supporting the use of adjuvant
cisplatin-based doublet chemotherapy after surgery for stages II
and III NSCLC, originating from 23 randomised trials
published between 1992 and 2005 [I, A]. Five ensuing meta-
analyses have been undertaken, summarising the beneﬁcial
effects as a hazard ratio ranging between 0.74 and 0.87 [23].
Individual patient data meta-analysis afﬁrmed the beneﬁcial
effects of cisplatin-based chemotherapy per subgroup of patients
with lung cancer, and it is recommended for stages II–III [24]
[I, A]. Most studies used a two-drug combination with cisplatin
and an attempted cumulative cisplatin dose of at least 300 mg/
m², delivered in three to four cycles. The most frequently used
regimen across trials is cisplatin–vinorelbine. Efﬁcacy in stage IB
remains controversial since the results are inconsistent in this
subgroup [II, B]. Data suggest that there is no overall survival
(OS) beneﬁt, except for patients with tumours >4 cm in the
CALGB 9633 study [25], or patients with tumours >5 cm in the
JBR.10 study [26]. Currently, adjuvant chemotherapy is not
recommended in stage IA, with reports of potential harm,
although the number of patients in this subgroup was small [II, B].
As lung cancer patients often have smoking-induced
cardiopulmonary co-morbidity, the indication of adjuvant
chemotherapy after thoracic surgery needs to be assessed
individually according to the risk-beneﬁt ratio. Age per se is not
a contra-indication for adjuvant chemotherapy [27]. Patients
must be well recovered following surgery.
In contrast, data regarding neo-adjuvant chemotherapy are
scarce. With 10 trials—some small-sized—addressing this
Figure 1. Suggested algorithm for locoregional lymph node staging in patients with non-metastatic non-small-cell lung cancer (adapted from De Leyn P,
Lardinois D, Van Schil PE, et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007; 32(1): 1–8.
By permission of Oxford University Press for the European Association for Cardio-Thoracic Surgery).
Table 1. Comparison of 5-year survival rates with surgery alone, surgery
followed by adjuvant chemotherapy or neo-adjuvant chemotherapy followed
by surgery. Data adapted from Lim et al. [23].
Stage
5-year survival
Postoperative
chemotherapy
Preoperative
chemotherapy
Reported Expected 95% CI Expected 95% CI
IA 73 78.4 76.4–80.3 78.1 73.7–81.8
IB 54 63.2 59.8–66.4 62.7 55.2–69.0
IIA 48 58.5 54.6–62.0 57.9 49.4–64.9
IIB 38 50.5 45.9–54.7 49.8 39.7–58.2
IIIA 25 40.1 34.5–45.3 39.3 27.0–49.4
Reproduced with permission from Lim et al. [23].
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question, the most recent published in 2011 [28], results are
largely dominated by the MRC LU22 study which reported a
favourable hazard ratio of 0.88 (P = 0.07) [29]. When the results
of adjuvant versus neo-adjuvant chemotherapy were compared
using indirect comparison meta-analysis [23] (Table 1), or
directly as in the NATCH trial [30], no clinically important
differences in OS were discerned. Induction chemotherapy can be
given with the intent of tumour down-staging allowing complete
resection, but this has not been evaluated in a formal randomised
setting [III, B]. However, indirect data from the MRC LU22 study
suggest that 31% of patients are down-staged as a result of
preoperative chemotherapy, even though, in this study, all
tumours were considered suitable for resection at baseline [29].
Several predictive factors for the use of adjuvant cisplatin-
based chemotherapy have been described, such as
immunohistochemistry staining for the DNA repair component
Excision Repair Cross Complementation Group 1 (ERCC1)
[31]. They should guide neither the indication of adjuvant
therapy nor the choice of therapy [IV, B], since ERCC1 ﬁndings
could not be validated in recent analyses [32], and none of these
markers has been prospectively validated in large cohorts. The
same holds true for molecular analyses for, for example, EGFR,
KRAS or ALKmutations. Actually, randomised study data
suggested a worse survival with postoperative use of the EGFR-
tyrosine kinase inhibitor geﬁtinib compared with placebo in the
adjuvant setting, even in the subgroup with EGFR-mutated
tumours [33]. Hence, at present, targeted agents should not be
used in the adjuvant setting [II, A].
primary radiotherapy
In patients unﬁt for surgery, SABR is the treatment of choice for
peripherally located stage I NSCLC (if SABR is not available, a
hypofractionated radiotherapy schedule with a high biologically
equivalent dose is advised) [III, A].
SABR has led to improved population-based survival in
elderly patients [34], and the convenience of this outpatient
therapy over three to eight visits has also led to a reduction in
the proportion of untreated patients. The SABR dose should be
to a biologically equivalent tumour dose of ≥100 Gy, prescribed
to the encompassing isodose.
A systematic review comparing outcomes of SABR and
surgery in patients with severe COPD revealed a higher 30-day
mortality following surgery but similar OS at 1 and 3 years [35].
Analysis of SABR outcomes in 676 patients found a median OS
of 40.7 months, and actuarial 5-year rates of initial local,
regional and distant recurrence of 10.5%, 12.7% and 19.9%,
respectively [36]. A systematic review of SABR in centrally
located tumours found local control rates of >85% with
biologically equivalent doses ≥100 Gy [37]. The risk of high-
grade toxic effect was <9% when the biologically equivalent
normal tissue dose was ≤210 Gy. Prospective trials of SABR
versus primary resection are now underway.
For tumours with a size >5 cm and/or central location, far less
data are available for SABR. These patients are preferentially
treated with radical radiotherapy using more conventional daily
or accelerated schedules [38] [III, A].
Adding chemotherapy to radiotherapy for patients with stage
II-N1 disease may be considered [V, C]. Although this was not
properly assessed in clinical studies, there may be a similar
beneﬁt as for resected patients with stage II-N1 disease.
postoperative radiotherapy
There is no indication that postoperative radiotherapy (PORT)
improves outcome in patients with completely resected N0 or
N1 disease, with a meta-analysis in fact demonstrating a
detrimental effect on survival in these cases [39]. For patients in
whom unsuspected mediastinal nodal metastases are discovered
during surgery, PORT has not been shown to improve OS in
prospective randomised studies. PORT in completely resected
early-stage NSCLC is therefore not recommended [I, A]. It can
however be indicated after incomplete surgery [III, B].
treatment of locally advanced stage III
chemotherapy
Chemotherapy is an integral part in the treatment of locally
advanced NSCLC (LA-NSCLC) as it improves survival in all
subgroups of patients, whether treated with surgery or
radiotherapy, as shown in meta-analyses based on individual
patient data [40, 41] [I, A].
The optimal chemotherapy regimen has not been investigated
in randomised studies which were speciﬁcally designed for this
purpose. In the absence of such trials, no strict recommendation
can be given as to the best combination. Of the six randomised
studies in the meta-analyses, ﬁve used cisplatin-based schedules
and only one carboplatin. In the carboplatin study, a weekly
infusion was used, but this relates to only 91 patients out of a
total of 1205 in the meta-analysis. Cisplatin-based schedules are
therefore recommended [II, A]. Moreover, in a recent meta-
analysis on risk factors for symptomatic radiation pneumonitis,
elderly patients who received carboplatin–paclitaxel
chemotherapy were at highest risk [42].
Of the ﬁve phase III studies that used cisplatin concurrently
with radiotherapy, two used only two cycles of chemotherapy
during radiotherapy, one trial used two cycles concomitantly
during radiotherapy followed by two cycles of consolidation
chemotherapy and two studies used daily cisplatin. There was
no signiﬁcant heterogeneity in the beneﬁt between these
schedules, although the daily administration of cisplatin has not
been adopted widely because of practical issues. Therefore, two
to four cycles of cisplatin-based doublet chemotherapy are
recommended [III, B]. The most commonly used drugs together
with cisplatin are etoposide (at full systemic dose 100–120 mg/m²)
and vinorelbine (at 60% of systemic dose, 15 mg/m²). On average,
a cisplatin dose of 80 mg/m2 per cycle was administered.
In a phase III study, patients were randomised between
carboplatin–paclitaxel induction chemotherapy followed by
either concurrent radiotherapy with the same chemotherapy or
concurrent chemoradiotherapy alone [43]. No differences in any
end point were observed with the exception of more
haematological toxic effect in the induction arm. Carboplatin-
based induction chemotherapy before concurrent chemo-
radiotherapy is therefore not recommended [I, C].
Consolidation treatment after concurrent chemoradiotherapy
either with docetaxel [44, 45] or with geﬁtinib [46] did not
result in improved survival in phase III studies—with even a
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detrimental effect regarding geﬁtinib—and is therefore not
recommended [I, A].
In sequential approaches, i.e. in the induction setting either
before surgery or radiotherapy, the same cisplatin-based doublet
regimens as in other NSCLC settings are recommended, with
the number of cycles ranging from two to four [I, A].
resectable LA-NSCLC
Patients are deﬁned as having potentially resectable LA-NSCLC
when a dedicated multidisciplinary assessment—including an
experienced thoracic surgeon—judges a complete resection (R0)
may be feasible after induction treatment. The treatment of LA-
NSCLC remains a matter of debate [47] (Figure 2). Aside from
many dedicated prospective studies on surgical multimodality
treatment in potentially resectable stage IIIA-N2 patients—
including more than 2000 patients—there is only one
randomised trial in this setting [48]. The Lung Intergroup Trial
0139 randomised patients with resectable N2 disease (75% had
single nodal station N2 disease) between either concurrent
radiotherapy to a dose of 45 Gy and cisplatin–etoposide
followed by surgery or deﬁnitive concurrent chemoradiotherapy
to a dose of 61 Gy. No signiﬁcant difference in OS was observed
(P = 0.24), but progression-free survival was signiﬁcantly better
in the trimodality arm (P = 0.017). This points to the possibly
higher early toxic death rate in the surgery arm as an
explanation for the non-signiﬁcant improvement in OS in the
surgical arm. This was indeed the case for patients having
pneumonectomy. In an exploratory unplanned, matched
subgroup analysis, patients treated with a lobectomy after
induction concurrent chemoradiotherapy had a signiﬁcantly
better survival than those treated non-surgically or with a
pneumonectomy.
Following the non-signiﬁcant difference in the primary end
point result in the only randomised trial, the choice of treatment
varies across countries and centres. The optimal treatment plan
is to be discussed in a multidisciplinary tumour board, taking
into account the local treatment expertise. Both deﬁnitive
chemoradiotherapy and induction therapy followed by surgery
are options [II, A]. Surgery is preferably considered in patients
in whom a complete resection by lobectomy is expected [II, B].
More complex surgical resections after induction treatment
should be carried out in experienced centres [III, B]. Down-
staging of the mediastinal nodes in the resection specimen is
associated with better prognosis.
A randomised phase III study compared induction chemo-
radiotherapy to a dose of 45 Gy followed by surgery to
induction chemotherapy followed by surgery and postoperative
radiotherapy [49]. No differences were observed.
unresectable LA-NSCLC
Patients are deﬁned as having unresectable LA-NSCLC when a
dedicated multidisciplinary assessment—including an
experienced thoracic surgeon—judges a complete resection (R0)
to be unlikely, even after induction treatment.
Figure 2. Suggested algorithm for treatment in patients with locoregional non-small-cell lung cancer, based on imaging, invasive lymph node staging tests
and multidisciplinary assessment.
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Table 2. Summary of recommendations
Incidence/Epidemiology
• Screening with low-dose CT reduces lung cancer-related mortality [I, A]. It is not yet ready for large-scale implementation, because of unanswered questions
regarding the deﬁnition of the at-risk population, timing, interval and method of CT (particularly 2D versus 3D evaluation), how to handle (false) positive
ﬁndings, and, especially, cost-effectiveness in relation to smoking cessation.
• Screening with low-dose CT should not be offered on an individual basis. It can, however, be considered for current or former heavy smokers (≥30 pack-
years or ≤15 years since smoking cessation) aged 55–74 years, who are well informed about potential beneﬁts and risks, and who are referred to a dedicated
screening programme in an experienced multidisciplinary team [I, B].
• Other screening methods, such as chest X-ray, sputum analysis or biomarkers are not recommended for clinical use [I, C].
Diagnosis
• Bronchoscopy is the recommended method of obtaining a pathological diagnosis of centrally located tumours [III, A].
• The diagnostic approach to non-calciﬁed pulmonary nodules should be based on existing guidelines [III, A].
• A pre-treatment pathological diagnosis is recommended. In some patients with clinical stage I/II lesions, this is not feasible, and a high likelihood of
malignancy based on assessment of clinical and imaging ﬁndings in an experienced multidisciplinary group may be considered sufﬁcient [III, A].
Staging and risk assessment
• In non-metastatic NSCLC, detailed locoregional staging, according to the seventh TNM staging system, and the cardiopulmonary ﬁtness of the patient
determine the choice of treatment [III, A].
• For patients with a non-centrally located resectable tumour and absence of nodal metastasis on both CT and PET images, surgical resection is recommended
[I, A].
• For patients with suspect mediastinal lymph node metastasis on CT or PET images (unless bulky) pathological conﬁrmation of nodal disease is
recommended [I, A].
• The preferred ﬁrst technique for pathological conﬁrmation of suspect nodes is needle aspiration under EBUS and/or EUS guidance. Mediastinoscopy is the
test with the highest negative predictive value to rule out mediastinal lymph node disease [I, A].
• The risk of postoperative morbidity and mortality should be estimated using validated risk-speciﬁc models [III, A].
• Formal lung function testing should be undertaken to estimate postoperative lung function. For patients with FEV1 and DLCO >80% in their pulmonary
function tests and no other major co-morbidities, surgical resection is recommended. For others, additional ergospirometry, echocardiography, coronary
tests etc. may be warranted [III, A].
• Co-morbidities should be evaluated and optimised before surgery [III, A].
Treatment of early stages I and II
• Surgery should be offered to patients with stage I or II NSCLC who are willing to accept procedure-related risks [III, A].
• Anatomical resection (lobectomy) is preferred over lesser resections such as wedge or segment resection [I, A].
• Lymph node dissection should conform to IASLC speciﬁcations for staging [III, A].
• Either open thoracotomy or VATS access can be utilised as appropriate to the expertise of the surgeon [III, A].
• Adjuvant chemotherapy should be offered to patients with resected stage II or III NSCLC [I, A] and can be considered in patients with resected stage IB
disease and a primary tumour >4 cm [II, B]. However, pre-existing co-morbidity and postoperative recovery need to be taken into account in this decision.
• For adjuvant chemotherapy, a two-drug combination with cisplatin is preferable [I, A]. In randomised studies, the attempted cumulative cisplatin dose was
up to 300 mg/m², delivered in three to four cycles. The most frequently studied regimen is cisplatin–vinorelbine.
• Given the current state of knowledge, the choice of adjuvant therapy should not be guided by molecular analyses such as ERCC1 or mutation testing [IV, B].
• Given the current state of knowledge, targeted agents should not be used in the adjuvant setting [II, A].
• In view of the equivalence of neo-adjuvant and adjuvant chemotherapy for overall survival, the consistent results and broad evidence base support adjuvant
chemotherapy as the timing of choice [I, A].
• The non-surgical treatment of choice for stage I NSCLC is stereotactic ablative radiotherapy (SABR). The dose should be to a biologically equivalent tumour
dose of ≥100 Gy, prescribed to the encompassing isodose [III, A].
• SABR for early-stage peripheral lung tumours is associated with low toxic effect in patients with COPD and the elderly [III, A].
• For tumours with a size >5 cm and/or central location, radical radiotherapy using more conventional daily or accelerated schedules is recommended [III, A].
• Postoperative radiotherapy in completely resected early-stage NSCLC is not recommended [I, A]. It can however be indicated after incomplete surgery [III, B].
Treatment of locally advanced stage III
• Chemotherapy should be offered to all patients with LA-NSCLC who can tolerate it [I, A].
• Cisplatin-based regimens (e.g. cisplatin–etoposide or cisplatin–vinorelbine) delivered concurrently with radiotherapy have been studied most extensively,
and are therefore recommended [II, A]. Studies using carboplatin–paclitaxel or other carboplatin-based combinations generally showed inferior outcomes,
but may be chosen individually based on co-morbidity issues. The number of cycles ranges from two to four, and the cisplatin dose per cycle was in the
range of 80 mg/m2 [III, B].
Continued
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In the EORTC (European Organisation for Research and
Treatment of Cancer) trial, patients with unresectable N2
disease who showed at least a minimal tumour response after
three cycles of very heterogeneous induction chemotherapy
protocols were randomised between radiotherapy (60 Gy in 30
fractions in 6 weeks) and surgery [50]. No survival differences
were observed. The preferred treatment of unresectable LA-
NSCLC is deﬁnitive concurrent chemotherapy and radiotherapy
with a dose no less than the biological equivalent of 60 Gy in
2.0 Gy fractions [I, A].
Induction chemotherapy followed by radiotherapy (mostly to
a dose of 60–66 Gy in 30–33 fractions in 6–7 weeks), so-called
sequential chemoradiotherapy, was compared with concurrent
chemoradiotherapy to the same dose in many phase III trials
and in a meta-analysis [51]. Concurrent chemotherapy and
radiotherapy lead to higher 5-year survival rates at the cost of a
higher rate of reversible oesophagitis. In ﬁt patients, this is the
standard treatment. Accurate locoregional staging is
recommended in analogy with resectable LA tumours [III, B].
In elderly patients or in those with clinically relevant co-
morbidities [13], sequential chemotherapy and radiotherapy is a
reasonable therapy choice [I, A]. A randomised trial in elderly,
frail patients reported better median survival when low-dose daily
carboplatin was added to radiotherapy alone [52]. In a meta-
analysis based on individual patient data from phase III trials,
accelerated radiotherapy schedules (i.e. delivered in shorter overall
treatment times) led to higher 5-year OS rates at the expense of
transient acute oesophagitis in patients treated with non-
concurrent schedules [38]. Accelerated radiotherapy schedules are
therefore recommended [I, A], e.g. 66 Gy in 24 fractions.
High-dose radiotherapy should be delivered according to
quality standards such as those of the EORTC [53].
postoperative radiotherapy
PORT may be considered for ﬁt patients with completely
resected NSCLC with N2 nodal involvement, preferably after
completion of adjuvant chemotherapy. This may reduce local
recurrences, although no survival beneﬁt has been demonstrated
[54] [III, B]. A randomised clinical trial to assess the effect on
survival is ongoing (LUNGART, NCT00410683). PORT can be
indicated in case of a R1 or R2 resection, although survival in
these patients remains poor [54] [III, B].
personalised medicine
In this disease setting, more research is needed to identify
molecular markers which could lead to advances in
personalised medicine.
follow-up
NSCLC patients treated with radical intent should be followed
for treatment-related complications, detection of treatable
relapse or occurrence of second primary lung cancer [III, A].
Except for one small underpowered study, there are no
prospective comparative trials on the question of what is the
most effective follow-up for patients with non-metastatic
NSCLC [55]. How often and by which methods surveillance is
indicated is guided by knowledge about relapse patterns, not by
evidence that earlier detection and treatment of recurrence leads
to a better outcome.
At least two-thirds of the relapses occur in the initial 2–3
years after treatment [56]. Hence, a follow-up visit every 3–6
months is recommended during 2–3 years, annually thereafter
Table 2. Continued
• In sequential approaches, a platinum-based two-drug combination is the preferred choice, with the number of cycles ranging from two to four [I, A].
• Carboplatin-based induction chemotherapy before concurrent chemoradiotherapy can generally not be recommended [I, C]. Data on cisplatin-based
induction chemotherapy are few and individual patients may beneﬁt from this approach [III, B].
• Consolidation treatment with, e.g. docetaxel or an EGFR-tyrosine kinase inhibitor after concurrent chemoradiotherapy is not recommended [I, A].
• The preferred treatment of unresectable LA-NSCLC is deﬁnitive concurrent chemotherapy and radiotherapy [I, A].
• Deﬁnitive thoracic radiotherapy should be no less than the biological equivalent of 60 Gy in 2.0 Gy fractions [I, A].
• In patients who are unﬁt to receive concurrent chemotherapy and radiotherapy, the sequential approach should be offered as an alternative treatment with
curative intent [I, A].
• In non-concurrent schedules, radiotherapy delivered in a short overall treatment time is recommended [I, A].
• For resectable LA-NSCLC, especially single nodal stage N2 disease, both deﬁnitive chemoradiotherapy and induction therapy followed by surgery are options
[II, A].
• Surgery is preferably considered in patients in whom a complete resection by lobectomy is expected [II, B]. More complex surgical resections after induction
treatment should be carried out in experienced centres [III, B].
• Routine use of PORT is, as yet, unproven but it may be considered in N2 patients after resection. In these cases, radiotherapy was delivered after
chemotherapy in randomised studies. PORT is indicated after incomplete surgery [III, B].
Follow-up
• NSCLC patients treated with radical intent should be followed for treatment-related complications, detection of treatable relapse or occurrence of second
primary lung cancer [III, A].
• A follow-up visit every 3–6 months is recommended during 2–3 years, less often—e.g. annually—thereafter [III, B].
• For follow-up, history and physical examination, chest CT and, to a lesser extent, chest X-ray, are appropriate tools [III, B].
• NSCLC patients should be offered smoking cessation, as this leads to superior treatment outcomes. Combining behaviour techniques with pharmacotherapy
is the preferred approach [I, A].
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[III, B]. New abnormalities deserve discussion in a
multidisciplinary team with experience in both treatment
complications, and in the distinction between recurrence or
metachronous second primary tumour, which occurs in 5–10%
of the patients.
History and physical examination, chest X-ray and annual CT
are appropriate tests, CT in particular for earlier detection of a
second primary tumour.
smoking cessation
Smoking is the main cause of lung cancer, responsible for 80%
of cases. Smoking cessation is of major value for NSCLC
patients—especially those with early and locally advanced stages
and a potential for cure—as it is associated with signiﬁcantly
decreased risks of mortality, development of a second primary
tumour lung cancer or recurrence [57]. Combining behaviour
techniques with pharmacotherapy is the best approach, with
success rates up to 25% [58] [I, A].
note
A summary of recommendations is given in Table 2. Levels of
evidence and grades of recommendation have been applied
using the system shown in Table 3. Statements without grading
were considered justiﬁed standard clinical practice by the
experts and the ESMO faculty.
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